Kornimate/medical-research-clean huggingface dataset:
otogenic csvt retrospective case series and associated thrombophilia

Conditions: Lateral Sinus Thrombosis; Mastoiditis; Otitis Media

Summary: the aim of this study is to report the clinical presentation, microbiological, laboratory and imaging evaluation, prothrombotic factors analysis, medical and surgical management and outcomes in children with otogenic cerebral sinus vein thrombosis (csvt).

objective: otogenic cerebral sinus vein thrombosis (csvt) is a rare but serious intracranial complication of otitis media in children. the aim of this study is to report the clinical presentation, microbiological, laboratory and imaging evaluation, prothrombotic factors analysis, medical and surgical management and outcomes in children with otogenic csvt. study design: retrospective case series

Eligibility criteria:
inclusion criteria: * age of 18 years or younger * both sexes are included * a clinical or radiological finding of mastoiditis in the patient's file * documentation of csvt in an imaging study, either ct or mri. patient's exclusion criteria * age above 18 years * lack of a clinical or radiological finding of mastoiditis in the patient's file * lack of documentation of csvt in an imaging study, either ct or mri. * previous unprovoked venous thromboembolism event.

Keywords: otitis media mastoiditis lateral sinus thrombosis subperiosteal abscess sigmoid sinus mastoid mastoidectomy ventilation tube
clinical research for the diagnosis of tick-borne diseases in patients with unexplained acute fever

Conditions: Fever of Unknown Origin; Tick-borne Diseases

Summary: the study will use several laboratory diagnoses in the diagnosis of patients with fever，to find out which will be more helpful for making an accurate diagnosis in the early period of tickborne diseases.

tickborne diseases(tbds) spread throughout many countries and regions. in recent years, the incidence has a tendency to rise continuously. the clinical symptoms and laboratory features of tick-borne diseases are always of no specific, and the diagnostic methods available, such as observing the pathogen after cultivation or by the method of gimenez、serological tests for antibody always can't make a timely diagnosis, especially in the early period of the disease. the development of polymerase chain reaction(pcr) has been applied for pathogen detection, and showed high sensitivity and specificity,and may contribute to early diagnose，but no standardized method of pcr has been as yet proposed. this study mean to explore several laboratory diagnoses to find out which will be more helpful for making an accurate diagnosis in the early period of tbds.

Eligibility criteria:
inclusion criteria: * patients have fever more than one week * temperature is higher than 38℃ celsius degree * full of physical examination and laboratory examination have been carried out after one week，but still cannot make a definite diagnosis exclusion criteria: * fever for non-infectious diseases such as rheumatic autoimmune disease or with tumor * we find that the patient selected does not meet the selection criteria within the observation period * patients leave with automatic discharge

Keywords: tbds；diagnosis
adira (anti-inflammatory diet in rheumatoid arthritis)

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a chronic inflammatory disease that affects 0.5-1% of the population, and where many patients in spite of modern pharmacological treatment fail to reach remission. the main goal of the randomized cross-over trial adira (anti-inflammatory diet in rheumatoid arthritis) is to test the hypothesis that a diet intervention will decrease disease activity and improve quality of life in patients with established ra.

rheumatoid arthritis (ra) is a chronic inflammatory disease that affects 0.5-1% of the population, and where many patients in spite of modern pharmacological treatment fail to reach remission. this affects physical as well as mental wellbeing and leads to severely reduced quality of life and reduced work capacity, thus yielding high individual as well as societal costs. to optimize treatment, alternatives such as diet should be evaluated as complement to pharmacological treatment. the main goal of the randomized cross-over trial adira (anti-inflammatory diet in rheumatoid arthritis) is to test the hypothesis that a diet intervention will decrease disease activity and costs and improve quality of life in patients with established ra. in total, 60 ra patients with moderate disease activity will be randomized to receive initially either a portfolio diet based on several food items with suggested anti-inflammatory effects or a control diet (western type), during 2 x 10 wks with a 3 months wash-out between diets. both groups continue with regular pharmacological treatment. known food biomarkers will be analyzed to measure intervention compliance. impact on disease activity (measured by das28, a composite score which predicts disability and progression of ra) and quality of life is evaluated after each diet regimen. metabolomics will be used to evaluate the potential to predict responders to dietary treatment. adira will provide evidence whether dietary treatment of ra leads to more patients reaching remission and improved quality of life and work capacity as well as reduce individual and societal costs. scientific evidence exists for anti-inflammatory effect by single foods on ra, but no study exists where these foods have been combined to obtain maximum effect and thus have the potential to offer a substantial improvement in patient life quality. such evidence has been asked for by ra patents as well as by treating physicians.

Eligibility criteria:
inclusion criteria: * subjects with established ra, disease duration \>2 years, disease activity das28 \>= 2.6 and a disease that is clinically stable and under adequate control and medication, will be invited to participate. exclusion criteria: * other life threatening diseases, pregnancy, lactation, food intolerance or allergy to food included in the trial, ability to understand information in swedish

Keywords: diet inflammation metabolomics
tobramycin-dexamethasone versus tobramycin-dexamethasone plus ketorolac after phacoemulsification surgery

Conditions: Cataract

Summary: this randomized controlled trial compares two regimens of topical therapy: * tobramycin 0.3% - dexamethasone 0.1% (tobradex®, alcon), one drop four times/day * combination of tobramycin 0.3% - dexamethasone 0.1% (tobradex®, alcon), one drop four times/day, plus ketorolac tromethamine 0.5% (acular®, allergan), one drop three times/day. the topical treatment is administered for 28 days after phacoemulsification. patients are independently assessed by two ophthalmologists. on day 28, patients are evaluated for * corneal edema * conjunctival redness * anterior chamber reaction. moreover, the cases necessitating continuation of treatment are compared in the two groups on day 28 and 42.


Eligibility criteria:
inclusion criteria: * phacoemulsification (due to cataract) * uneventful phacoemulsification surgery exclusion criteria: * disruption of the anterior lens capsule * age-related macular degeneration * proliferative diabetic retinopathy * glaucoma

Keywords: cataract phacoemulsification treatment duration
gilead sustained virologic response (svr) registry

Conditions: Hepatitis C, Chronic

Summary: this registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (svr) while participating in a previous gilead sponsored hepatitis c virus (hcv) study. this long term follow up study is observational and no treatment is provided for hcv.


Eligibility criteria:
key inclusion criteria: * have previously participated in a gilead-sponsored hepatitis c study and received at least one gilead oral antiviral agent (oav) * have achieved svr in a gilead-sponsored study, as defined in the original treatment protocol * provide written, informed consent * be willing and able to comply with the visit schedule and protocol-mandated procedures key exclusion criteria: * individuals planning to start a new course of hepatitis c therapy including any investigational drug or device during the course of the follow-up registry * history of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hepatitis c hcv sustained virologic response direct acting antiviral combination therapy tegobuvir registry hcv rna treatment experienced treatment naive gs 9451 gs 5885 gs 7977 gs 5816 sofosbuvir sovaldi™ sof ledipasvir ldv
study of apr-1051 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: the purpose of this study is to assess the safety and effectiveness of apr-1051 through the performance of a phase 1, open-label, safety, pk, and preliminary efficacy study of oral apr-1051 in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of advanced/metastatic solid tumor * measurable or evaluable disease per recist version 1.1 (radiographic disease progression per pcwg3 criteria for patients with mcrpc) * eastern cooperative oncology group (ecog) performance status ≤ 1 or karnofsky performance status (kps) ≥ 70% * patients must have recovered to grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding grade ≤ 2 neuropathy, alopecia, or skin pigmentation * adequate bone marrow and organ function * women of child-bearing potential (wocbp) or men of child-fathering potential must agree to use adequate contraception prior to study entry exclusion criteria: * patient has had prior systemic anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy) within 3 weeks (6 weeks in cases of mitomycin c, nitrosourea, lomustine) or at least 5 half-lives (whichever is shorter, but no less than 2 weeks) prior to day 1 * prior radiation therapy at the target lesion unless there is evidence of disease progression. if patient has had prior radiation therapy for disease progression, see exclusion criterion 1 for allowed interval between radiotherapy and day 1 and recovery of aes * treatment with any investigational agent administered within 30 days or 5 half-lives, whichever is shorter, before the first dose of apr-1051 * major surgery within 21 days prior to day 1 * concomitant treatment with other anti-cancer therapy, including chemotherapy, immunotherapy, biological therapy, radiation therapy (except palliative local radiation therapy), or other novel anti-cancer agents. note: endocrine therapy for breast and prostate cancer is allowed along with agents to treat or prevent skeletal related events (zoledronic acid, pamidronate, denosumab) * subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy
doppler-based renal resistive index in assessing renal dysfunction reversibility in icu patients

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) is common in intensive care unit (icu) patients and remains associated with a dismal prognosis. the diagnosis of aki relies on functional criteria (oliguria and serum creatinine elevation), which carry several important limitations. additionally, the investigators lack biomarker that may predict short term renal prognosis. doppler-based renal resistive index (ri) measurement is a rapid and noninvasive investigative tool that may hold promise for early aki detection in icu patients or in differentiating transient from persistent aki in selected critically ill patients. although several studies have suggested adequate performance in predicting short-term reversibility of aki, most of these studies were performed in limited patient samples. additionally, a recent study has identified discrepant results regarding its diagnostic performance. the main objective of this large prospective multicentre study is to assess diagnostic performance of doppler-based renal resistive index in diagnosing persistent aki in critically ill patients requiring mechanical ventilation.


Eligibility criteria:
inclusion criteria: * sinus rhythm * use of conventional mechanical ventilation exclusion criteria: * refusal: patient, family or trusted person to participate in the study * renal artery stenosis known * pregnant * severe chronic renal failure (clearance \< 30 ml.min-1)

Keywords: icu patients doppler-based renal
chlorhexidine lavage for recurrent urinary tract infection

Conditions: Urinary Tract Infections; Recurrent Urinary Tract Infection

Summary: a two-arm randomized control trial evaluating rates of urinary tract infection in post-menopausal women on vaginal estrogen with recurrent urinary tract infections.

there is a critical need for low-cost, non-antibiotic interventions that are feasible for patients to utilize for risk reduction and prevention of recurrent urinary tract infections (utis). the current most effective non-antibiotic prophylaxis for recurrent uti is vaginal estrogen; however, approximately 50% of women will continue to experience utis. the investigators propose a randomized control trial of postmenopausal women on vaginal estrogen with the diagnosis of recurrent utis to evaluate a novel post-defecation hygienic strategy utilizing a 2% chlorhexidine perineal lavage. participants will be randomized to either a 2% chlorhexidine perineal lavage or a water lavage. study participants will be followed for up to 6-months, and utis will be tracked with culture proven samples throughout study participation.

Eligibility criteria:
inclusion criteria: * post-menopausal female between age 55 and 89 * no post-menopausal bleeding * diagnosis of recurrent urinary tract infection (uti) in the electronic health record or as two culture proven utis in 6 months or three culture proven utis in 12 months * at least one uti in the 6 months prior to entering the study * asymptomatic for uti symptoms at the time of enrollment. * on vaginal estrogen therapy for at least 6 weeks prior to enrollment * ready access to email and internet exclusion criteria: * recent prophylactic antibiotic use (washout period of 4 weeks) * neurogenic bladder * diagnosis of urinary retention * uncorrected stage iii-iv prolapse * indwelling catheter or need for intermittent self-catheterization * history of complicated utis * history of interstitial cystitis or bladder pain syndrome * history of fecal incontinence/accidental bowel leakage * greater than 14 bowel movements per week * non-english speaking * allergy to chlorhexidine gluconate * inability to utilize vaginal estrogen therapy * recent urogynecological or urologic surgery (\<12 weeks)

Keywords: menopause
a study on the efficacy of immunotherapy, the occurrence and severity of adverse reactions in patients with non-small cell lung cancer in high-altitude areas

Conditions: Non-small Cell Lung Cancer(NSCLC)

Summary: as a major disease with high incidence and mortality rate, lung cancer seriously threatens the health of our people and causes a huge burden of disease. in recent years, with the widespread use of immune checkpoint inhibitors (icis), great progress has been made in the treatment of lung cancer, which has brought significant survival benefits to patients. although ici has greatly improved the prognosis of lung cancer patients, due to the complexity of the mechanism of action of ici and the heterogeneity within the tumor, the benefit population of treatment is relatively limited, and some patients are still at risk of primary drug resistance and tumor hyperprogression.in this study, we aimed to compare the differences in the efficacy and adverse reactions of immunotherapy in patients with advanced non-small cell lung cancer at high and low altitudes, and to find out the relevant factors from multiple omics such as imaging, pathology, and genetics, so as to solve the problem of immunotherapy resistance


Eligibility criteria:
inclusion criteria: * (1) patients with primary non-small cell lung cancer (adenocarcinoma/squamous cell carcinoma/adenosquamous cell carcinoma/large cell lung cancer/others) with clear cellular/histopathological evidence; (2) primary non-small cell lung cancer of any stage receiving immunotherapy for the first time; (3) patients who have undergone at least 2 cycles of immunotherapy during the treatment period and have undergone one efficacy evaluation; (4) patients with at least one evaluable target lesion (except for those with uncontrolled brain metastases) according to response evaluation criteria for solid t tumors (recist, version 1.1); (5) voluntary participation in research and strong willingness to cooperate; (6) has been residing in qinghai province since birth; (7) have been residing in shaanxi province since birth; (8) be at least 18 years old; exclusion criteria: 1. patients with unknown histopathological type were excluded; 2. patients with unclear diagnosis and treatment information and immunotherapy-related adverse reactions; 3. patients with bipolar/multiple primary non-small cell lung cancer with other tumors were excluded; 4. patients who are unwilling to join the study and have poor willingness to cooperate; 5. patients who migrated to qinghai or shaanxi from different altitudes and had a history of migration between the two provinces were excluded; 6. exclude patients with a history of emigration from parents; 7. patients who have received immunotherapy for other tumors in the past; 8. prior immunosuppressive therapy prior to exclusion
phase 1 study of tg01 and erlotinib in non-small cell lung cancer (ncslc) patients

Conditions: Non-small Cell Lung Cancer

Summary: this is a multicenter, open-label, phase 1, dose escalation study. the purpose is to determine the highest dose of tg01 that can be safely given to patients with non-small cell lung cancer in combination with erlotinib.


Eligibility criteria:
inclusion criteria (include but are not limited to): * histogically or pathologically determined relapsed/recurrent stage iiib (plueral effusion) or iv nsclc. * measurable or evaluable disease as defined by recist * must have failed at least one prior chemotherapy regimen or have refused chemotherapy. * ecog perfromance status of 0,1, or 2. exclusion criteria (include but are not limited to): * radiation therapy (excluding cns therapy) \< 2 weeks, chemotherapy, non-cytotoxic investigational agents or high dose corticosteroids within 3 weeks of intitating therpy or patients who have not recovered from adverse effects due to agents administered more than 3 weeks earlier. * evidence of new york heart associatation class iii or greater cardiac disease. * history of myocardial infarction, stroke, or cardiovascular intervention within the last 12 months. * patients on anti-platlet drugs or anticoagulants such as placix and coumadin. * systemic central nervous system metastases. the patient must be stable after radiotherapy for \>/= to 2 weeks and off corticosteroids for \>/= to 1 week. * pregnant or nursing women. * patients who are primarily refactory to erlotinib.
sleep quality in (copd) patients (copd: chronic obstructive pulmonary disease)

Conditions: COPD

Summary: patients with copd, in addition to daytime symptoms, may suffer from nocturnal disturbances. the frequency of nocturnal problems has been reported to be higher in copd than in the general population and it currently affects up to 50% of patients. the casis questionnaire includes 7 questions and it has been recently validated as an objective tool to evaluate nocturnal symptoms in patients with asthma and copd. the present study aims to study the validity of the casis questionnaire as a predictor of sleep quality measured by objective polysomnographic parameters.


Eligibility criteria:
inclusion criteria: patients with written inform consent to participate in the study and all the following criteria will be selected: * age 40-80 years * smokers or exsmokers of at least 10 pack-years * moderate-to-severe copd exclusion criteria: * non-stable copd. stability is defined as being exacerbation free and without treatment changes for at least 4 weeks prior to baseline evaluation. the presence of a copd exacerbation previous to the sleep studies (polysomnography, actigraphy, osler test) will lead to an early discontinuation of the patient´s participation in the study. * heart failure, asthma, cancer or other major medical illness with known effects on sleep quality. * unable to understanding the questionnaires administered in the study. * known obstructive sleep apnea, other sleep disorder (narcolepsy, periodic limb movements) or shift work. * chronic respiratory failure (pao2 \<60 mmhg). * treatment with sedatives or antidepressants.
use of capnography as surrogate measure of pc02 in medical intensive care unit (icu) patients

Conditions: Asthma; Chronic Obstructive Pulmonary Disease; Interstitial Lung Disease

Summary: the purpose of this study is to evaluate the use of capnography (continuous recording of the carbon dioxide content of expired air)as an alternative test to measure pc02 levels in patients with asthma, chronic obstructive pulmonary (copd,interstitial lung disease(ild)or coronary disease who are at risk of intubation.

this is a prospective study to evaluate the usefulness of capnography as a non-invasive, accurate method of measuring of pc02 levels in medical intensive care unit patients with asthma, copd, ild, or coronary disease who are at risk of intubation.

Eligibility criteria:
inclusion criteria: * medical intensive care patients * not intubated * age 18 or older * history of any one of the following: asthma, copd, ild, or coronary disease exclusion criteria: * sepsis * life expectancy less than 1 month * requiring bipap

Keywords: pc02 respiratory rate arterial blood gas intubation capnography
the valsalva urethral profile : a measure to assess stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: clinical and paraclinical appraisal of stress urinary incontinence (sui) is mainly based on the assessment of pelvic floor muscles (pfm) contraction and urethral mobility, the measurement of the maximum urethral closure pressure (mucp) at rest by urethral pressure profilometry (upp) and the measurement of the valsalva leak point pressure (vlpp). currently, mucp and vlpp cannot be used for diagnosing sui because they appear to be moderately correlated with the severity of sui. the lack of a specific sui biomarker could be the explanation for the poor predictive value of urodynamics and the ongoing debate on whether urodynamic testing before surgery has benefits. our main objective was to study the value of a new urodynamic parameter in the diagnosis of female sui: the valsalva urethral profile (vup)


Eligibility criteria:
inclusion criteria: * women over the age of 18 years, referred for urodynamic exploration of the lower urinary tract, with or without lower urinary tract disorders (tuba) * women who gave their consent to participate in the study. exclusion criteria: * pelvic organ prolapse (pop) ≥ stage 2 according to the pop-q classification * history of surgery for sui and / or pop, * acute urinary tract infection, * proven neurological pathology, * urine retention, * a history of pneumothorax * a lability of mucp ≥ 15 cmh2o

Keywords: stress urinary incontinence urodynamics maximal urethral cloture pressure bladder neck mobility